Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Yoshihiro Komohara

Yoshihiro Komohara

Kumamoto University, Japan

Title: The significance of lymph node macrophages in the induction of anti-cancer immune response

Biography

Biography: Yoshihiro Komohara

Abstract

It is well known that many macrophages are distributed in lympho-reticular organs including spleen and lymph node (LN). Spleen and LNs are respectively involved in the filtration of lymph and blood flow, and immune responses are induced by activation of lymphocytes and natural killer cells which are dependent on antigen presenting cells (APCs) including dendritic cells and macrophages. CD169 (sialoadhesin) is a sialic acid receptor that is specifically expressed on macrophages, including lymph node sinus macrophages. Animal studies suggested that CD169+ macrophages in lymph nodes have tumor preventing properties; however, the role of these cells in the pathogenesis of human tumors has not been clarified. In order to determine the significance of CD169+ macrophages in cancer patients, we employed tissue samples from patients with malignant tumor including malignant melanoma and colorectal cancer and evaluated the relationships of this expression with overall survival and various clinicopathological factors. The high density of CD169+ cells was found to be significantly associated with a longer overall survival in the patients with malignant melanoma, colorectal cancer, and endometrial cancer. Positive correlations were noted between the density of CD169+ macrophages and the density of CD8+ cytotoxic T cells infiltrating tumor tissues. CD169+ macrophages in lymph node are suggested to be involved in T cell-mediated antitumor immunity and may be a useful marker for assessing the clinical prognosis and monitoring antitumor immunity in patients with malignant tumors.